Journal Mobile Options
Table of Contents
Vol. 26, No. 4, 2008
Issue release date: October 2008
Dement Geriatr Cogn Disord 2008;26:300–305

Apolipoprotein E Polymorphism and Brain Morphology in Mild Cognitive Impairment

Thomann P.A. · Roth A.-S. · Dos Santos V. · Toro P. · Essig M. · Schröder J.
aSection of Geriatric Psychiatry, University of Heidelberg, and bGerman Cancer Research Center, Heidelberg, Germany

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: The apolipoprotein E (ApoE) genotype has been confirmed as the major genetic risk factor for late-onset Alzheimer’s disease (AD). How the ApoE genotype and brain morphology relate to each other is only partly understood, particularly in mild cognitive impairment, the assumed prestage of AD. Methods: A total of 83 subjects with mild cognitive impairment (aging-associated cognitive decline criteria) were investigated with optimized voxel-based morphometry (VBM). We tested for differences in gray and white matter densities between groups according to their ApoE status, i.e. ε4 allele noncarriers (n = 42), subjects with one ε4 allele (n = 27) and subjects with two ε4 alleles (n = 14). Results: In individuals carrying two ε4 alleles, VBM revealed a decline in gray matter density predominantly in the medial temporal lobe region. Subjects with a single copy of the ε4 allele exhibited gray matter atrophy in the right inferior frontal gyrus. With respect to white matter changes, atrophy was only found in subjects homozygous for ε4 and confined to the right superior and middle temporal gyrus. Conclusion: Our findings support the hypothesis that the ApoE genotype in mild cognitive impairment might be associated with structural changes typically found in the early stages of AD.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Raber J, Huang Y, Ashford JW: ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol Aging 2004;25:641–650.
  2. Mahley RW: Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science 1988;240:622–630.
  3. Zannis VI, Breslow JL, Utermann G, Mahley RW, Weisgraber KH, Havel RJ, Goldstein JL, Brown MS, Schonfeld G, Hazzard WR, Blum C: Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes. J Lipid Res 1982;23:911–914.
  4. Huang Y: Apolipoprotein E and Alzheimer disease. Neurology 2006;66:S79–S85.
  5. Cherbuin N, Leach LS, Christensen H, Anstey KJ: Neuroimaging and APOE genotype: a systematic qualitative review. Dement Geriatr Cogn Disord 2007;24:348–362.
  6. Pennanen C, Testa C, Boccardi M, Laakso MP, Hallikainen M, Helkala EL, Hanninen T, Kivipelto M, Kononen M, Nissinen A, Tervo S, Vanhanen M, Vanninen R, Frisoni GB, Soininen H: The effect of apolipoprotein polymorphism on brain in mild cognitive impairment: a voxel-based morphometric study. Dement Geriatr Cogn Disord 2006; 22:60–66.
  7. Bartzokis G, Lu PH, Geschwind DH, Edwards N, Mintz J, Cummings JL: Apolipoprotein E genotype and age-related myelin breakdown in healthy individuals: implications for cognitive decline and dementia. Arch Gen Psychiatry 2006;63:63–72.
  8. Persson J, Lind J, Larsson A, Ingvar M, Cruts M, Van Broeckhoven C, Adolfsson R, Nilsson LG, Nyberg L: Altered brain white matter integrity in healthy carriers of the APOE epsilon4 allele: a risk for AD? Neurology 2006;66:1029–1033.
  9. Levy R: Aging-associated cognitive decline: Working Party of the International Psychogeriatric Association in collaboration with the World Health Organization. Int Psychogeriatr 1994;6:63–68.
  10. Ritchie K, Artero S, Touchon J: Classification criteria for mild cognitive impairment: a population-based validation study. Neurology 2001;56:37–42.
  11. Schönknecht P, Pantel J, Kruse A, Schröder J: Prevalence and natural course of aging-associated cognitive decline in a population-based sample of young-old subjects. Am J Psychiatry 2005;162:2071–2077.
  12. Folstein MF, Folstein SE, McHugh PR: ‘Mini-mental state’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–198.
  13. Morris JC, Heyman A, Mohs RC, Hughes JP, van Belle G, Fillenbaum G, Mellits ED, Clark C: The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). I. Clinical and neuropsychological assessment of Alzheimer’s disease. Neurology 1989;39:1159–1165.
  14. Aslanidis C, Schmitz G: High-speed apolipoprotein E genotyping and apolipoprotein B3500 mutation detection using real-time fluorescence PCR and melting curves. Clin Chem 1999;45:1094–1097.
  15. Good CD, Johnsrude IS, Ashburner J, Henson RN, Friston KJ, Frackowiak RS: A voxel-based morphometric study of ageing in 465 normal adult human brains. Neuroimage 2001;14:21–36.
  16. Farlow MR, He Y, Tekin S, Xu J, Lane R, Charles HC: Impact of APOE in mild cognitive impairment. Neurology 2004;63:1898–1901.
  17. Fleisher A, Grundman M, Jack CR Jr, Petersen RC, Taylor C, Kim HT, Schiller DH, Bagwell V, Sencakova D, Weiner MF, DeCarli C, DeKosky ST, van Dyck CH, Thal LJ: Sex, apolipoprotein E epsilon 4 status, and hippocampal volume in mild cognitive impairment. Arch Neurol 2005;62:953–957.
  18. Wang PN, Liu HC, Lin KN: The MCI study in Taiwan. Acta Neurol Taiwan 2006;15:66–68.

    External Resources

  19. Ashburner J, Friston KJ: Voxel-based morphometry – the methods. Neuroimage 2000;11:805–821.
  20. Nierenberg J, Pomara N, Hoptman MJ, Sidtis JJ, Ardekani BA, Lim KO: Abnormal white matter integrity in healthy apolipoprotein E epsilon4 carriers. Neuroreport 2005;16:1369–1372.
  21. Wishart HA, Saykin AJ, McAllister TW, Rabin LA, McDonald BC, Flashman LA, Roth RM, Mamourian AC, Tsongalis GJ, Rhodes CH: Regional brain atrophy in cognitively intact adults with a single APOE epsilon4 allele. Neurology 2006;67:1221–1224.
  22. Chen K, Reiman EM, Alexander GE, Caselli RJ, Gerkin R, Bandy D, Domb A, Osborne D, Fox N, Crum WR, Saunders AM, Hardy J: Correlations between apolipoprotein E epsilon4 gene dose and whole brain atrophy rates. Am J Psychiatry 2007;164:916–921.
  23. Braak H, Braak E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239–259.
  24. Hämäläinen A, Grau-Olivares M, Tervo S, Niskanen E, Pennanen C, Huuskonen J, Kivipelto M, Hanninen T, Tapiola M, Vanhanen M, Hallikainen M, Helkala EL, Nissinen A, Vanninen RL, Soininen H: Apolipoprotein E epsilon 4 allele is associated with increased atrophy in progressive mild cognitive impairment: a voxel-based morphometric study. Neurodegener Dis 2008;5:186–189.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50